Pancreatic cancer remains a deadly disease with limited treatment options. The current standards of treatment are mFOLFIRINOX and gemcitabine + Abraxane. Market growth over the forecast period to 2020 will be driven by the premium-priced products Abraxane and Onivyde and then, over the five years to 2025, by the new product introductions of Lynparza and PEGPH20. Longer-term promise lies in emerging dual and multiple combinations of targeted agents, particularly the PD-1 and PD-L1 checkpoint inhibitors.
Pancreatic Cancer - Landscape & Forecast - Disease Landscape & Forecast
Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is less than 10%. Treatment options for pancreatic cancer are limited to surgery, radiation,...